Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new combo therapy for leukemia patients shows potential in major trial

NCT ID NCT04530565

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 6 times

Summary

This study is for adults aged 18 to 75 with a specific type of leukemia called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It compares the usual treatment (steroids, a targeted drug, and chemotherapy) with the same treatment plus an extra drug called blinatumomab. The goal is to see if adding blinatumomab helps people live longer and reduces the amount of cancer left after treatment. The trial is active but no longer recruiting new participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 348 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ELIGIBILITY CRITERIA FOR PRE-REGISTRATION (TO STEP 0) * Patient must be \>= 18 and =\< 75 years of age * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-3 * Patient must be newly diagnosed with B acute lymphoblastic leukemia (B-ALL) or is suspected to have acute lymphoblastic leukemia (ALL) * Patient must have BCR-ABL1 positive disease. The diagnosis of ALL and the presence of BCR-ABL translocation must be confirmed centrally. Patients can be registered and begin step 1 therapy while awaiting central laboratory eligibility confirmation * NOTE: Bone marrow aspirate and/or peripheral blood specimen must be submitted to the ECOG-American College of Radiology Imaging Network (ACRIN) Leukemia Laboratory at MD Anderson Cancer Center to determine patient's eligibility for registration to Step 1 or confirm patient evaluability. Centrally fluorescence-activated cell sorting (FACS) analysis will be performed to determine B-ALL and to exclude acute myeloid leukemia (AML) or acute bi-phenotypic leukemia and baseline BCR-ABL status will be determined by fluorescent in situ hybridization (FISH). The ECOG-ACRIN Leukemia Laboratory will forward results within 48 hours of receipt of the specimen to the submitting institution. Bone marrow aspirate is to be from first pull (initial or re-direct). Specimens must contain sufficient blast cells. In cases where the bone marrow aspiration may be inadequate, or the bone marrow examination has already been performed prior to study consent and enrollment on Step 0, peripheral blood may be submitted, with recommendation that adequate circulating blasts are present (\> 10%). If a diagnosis of BCR-ABL positive B-ALL has already been established by local Clinical Laboratory Improvement Act (CLIA) certified laboratories, the patient may be registered to step 1 without waiting for central confirmation * Patient must not have a diagnosis of BCR/ABL T-ALL * Patient must not have received chemotherapy for B-ALL. Patients who received up to five days of therapy (hydroxyurea and/or steroids of any kind) with the aim to reduce disease burden prior to study registration to Step 1 are eligible * Patient must not have unstable epilepsy that requires treatment * Patients with lymphoid blast crisis chronic myeloid leukemia (CML) are not eligible * ELIGIBILITY CRITERIA FOR REGISTRATION TO STEP 1 * Patient must have a diagnosis of Philadelphia chromosome positive (Ph+) ALL that has been determined locally and bone marrow and/or peripheral blood was sent and receipt confirmed for central confirmation or determined centrally by the ECOG-ACRIN Leukemia Laboratory at MD Anderson Cancer Center * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any woman, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of step 1 registration, while on study treatment, and until at least six months after the last dose of study treatment * Total bilirubin =\< 3 mg/dL (patients with Gilbert's syndrome must have a total bilirubin =\< 5 mg/dL) (obtained =\< 28 days prior to step 1 registration) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X the institutional upper limit of normal (ULN) (obtained =\< 28 days prior to step 1 registration) * Estimated creatinine clearance \> 45 mL/min (based on Cockcroft-Gault equation) (obtained =\< 28 days prior to step 1 registration) * Patients with acute organ dysfunction at step 1 registration, which may be attributed to leukemia can be registered regardless of lab results at presentation. Such patients will be allowed to register and can start Arm A steroid + TKI therapy but will only be allowed to proceed to step 2 randomization if the eligibility criteria outlined is met * Patients who presented with no evidence of acute organ dysfunction but during step 0 experienced a rise in liver enzymes which investigator suspects to be a side effect of any of prescribed drugs, are allowed to be registered regardless of the level of liver enzymes. Step 2 randomization must be withheld until the eligibility criteria outline is met but no more than 14 days after concluding Arm A therapy * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable or on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have an undetectable HCV viral load and if indicated, on treatment * Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patient must not have active concomitant malignancy. Patients on chronic hormonal therapy for breast or prostate cancer or patients treated with maintenance with targeted agents but are in remission with no evidence for the primary malignancies are eligible * Patient must not have complaints of symptoms and/or have clinical and/or radiological signs that indicate an uncontrolled infection or any other concurrent medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better * Investigators must confirm which TKI patient is to receive * NOTE: Patients with known T315I mutation status should receive ponatinib treatment * NOTE: In situations due to insurance coverage issues and the pre-selected TKI is not immediately available, patients can receive dasatinib or imatinib during step 1. The investigator must re-specify dasatinib or ponatinib prior to step 2 randomization and from then on patients must receive the pre-selected TKI only * ELIGIBILITY CRITERIA FOR RANDOMIZATION TO STEP 2 * Patient must have completed at least 7 and no more than 21 days of protocol-treatment on Arm A prior to step 2 randomization. (Days in which arm A therapy was withheld for any reason are not counted) * NOTE: First day of steroids prescription after registration will be considered as the first day of study therapy. The selected TKI must be initiated prior to randomization * Patients who presented with acute organ dysfunction within 2 weeks of registration to step 1 must have total bilirubin =\< 2 X institutional upper limit of normal (ULN) * AST(SGOT) and ALT(SGPT) =\< 2 X the institutional upper limit of normal (ULN) * Estimated creatinine clearance \> 45 mL/min (based on Cockcroft-Gault equation) * Investigators must confirm which TKI patient is to receive. * NOTE: Patients with known T315I mutation status should receive ponatinib treatment * For patients under age 70, intended chemotherapy regimen must have been determined prior to randomization * Patient must not have active central nervous system (CNS) involvement by leukemic blasts. Patients with signs of CNS involvement at presentation are eligible for randomization if clearance of blasts from the cerebrospinal fluid (CSF) is demonstrated * Patients must have resolved any serious infectious complications related to therapy * Any significant medical complications related to therapy must have resolved * ELIGIBILITY CRITERIA FOR REGISTRATION TO STEP 3 (RE-INDUCTION) * Institution has received centralized MRD results confirming positive status * Patients who presented with acute organ dysfunction within 2 weeks of registration to step 1 must have total bilirubin =\< 2 X institutional ULN * Patients who presented with acute organ dysfunction must have AST (SGOT)/ALT (SGPT) =\< 2 X institutional upper limit of normal (ULN) * Patients who presented with acute organ dysfunction must have an estimated creatinine clearance \> 45 mL/min (based on Cockcroft-Gault equation) * Investigators must confirm which TKI patient is to receive * NOTE: Patients with known T315I mutation status should receive ponatinib treatment * For patients under age 70 and previously assigned to Arm C, intended chemotherapy regimen must have been determined * Step 3 (Re-Induction): Patients must have resolved any serious infectious complications related to therapy * Step 3 (Re-Induction): Any significant medical complications related to therapy must have resolved

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B acute lymphoblastic leukemia with T(9;22)(Q34.1;Q11.2); BCR-ABL1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B acute lymphoblastic leukemia with T(9;22)(Q34.1;Q11.2); BCR-ABL1

Contacts and locations

Locations

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska, 99508, United States

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska, 99508, United States

  • Alaska Women's Cancer Care

    Anchorage, Alaska, 99508, United States

  • Allegiance Health

    Jackson, Michigan, 49201, United States

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska, 98508, United States

  • Anchorage Oncology Centre

    Anchorage, Alaska, 99508, United States

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska, 99504, United States

  • Augusta University Medical Center

    Augusta, Georgia, 30912, United States

  • Baptist Memorial Hospital and Cancer Center-Desoto

    Southhaven, Mississippi, 38671, United States

  • Baptist Memorial Hospital and Cancer Center-Memphis

    Memphis, Tennessee, 38120, United States

  • Bay Area Hospital

    Coos Bay, Oregon, 97420, United States

  • Cancer Hematology Centers - Flint

    Flint, Michigan, 48503, United States

  • Case Western Reserve University

    Cleveland, Ohio, 44106, United States

  • Central Care Cancer Center - Bolivar

    Bolivar, Missouri, 65613, United States

  • Central Care Cancer Center - Garden City

    Garden City, Kansas, 67846, United States

  • Central Care Cancer Center - Great Bend

    Great Bend, Kansas, 67530, United States

  • Centro Comprensivo de Cancer de UPR

    San Juan, 00927, Puerto Rico

  • Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Clackamas Radiation Oncology Center

    Clackamas, Oregon, 97015, United States

  • Community Cancer Institute

    Clovis, California, 93611, United States

  • CoxHealth South Hospital

    Springfield, Missouri, 65807, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Freeman Health System

    Joplin, Missouri, 64804, United States

  • Geisinger Medical Center

    Danville, Pennsylvania, 17822, United States

  • Geisinger Wyoming Valley/Henry Cancer Center

    Wilkes-Barre, Pennsylvania, 18711, United States

  • Genesee Hematology Oncology PC

    Flint, Michigan, 48503, United States

  • Genesys Hurley Cancer Institute

    Flint, Michigan, 48503, United States

  • Gundersen Lutheran Medical Center

    La Crosse, Wisconsin, 54601, United States

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii, 96701, United States

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii, 96813, United States

  • Hawaii Cancer Care Inc-Liliha

    Honolulu, Hawaii, 96817, United States

  • Heartland Regional Medical Center

    Saint Joseph, Missouri, 64506, United States

  • Hematology Oncology Consultants-Clarkston

    Clarkston, Michigan, 48346, United States

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan, 48183, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb Health Center - Shelby Township

    Shelby, Michigan, 48315, United States

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan, 48038, United States

  • Henry Ford Medical Center-Columbus

    Novi, Michigan, 48377, United States

  • Henry Ford Medical Center-Fairlane

    Dearborn, Michigan, 48126, United States

  • Henry Ford Saint John Hospital - Macomb Medical

    Macomb, Michigan, 48044, United States

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan, 48322, United States

  • Henry Ford Wyandotte Hospital

    Wyandotte, Michigan, 48192, United States

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Hurley Medical Center

    Flint, Michigan, 48503, United States

  • Huron Gastroenterology PC

    Ypsilanti, Michigan, 48106, United States

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington, 99336, United States

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii, 96826, United States

  • Katmai Oncology Group

    Anchorage, Alaska, 99508, United States

  • Kuakini Medical Center

    Honolulu, Hawaii, 96817, United States

  • LSU Health Sciences Center at Shreveport

    Shreveport, Louisiana, 71103, United States

  • Lehigh Valley Hospital - Muhlenberg

    Bethlehem, Pennsylvania, 18017, United States

  • Lehigh Valley Hospital-Cedar Crest

    Allentown, Pennsylvania, 18103, United States

  • Lehigh Valley Hospital-Hazleton

    Hazleton, Pennsylvania, 18201, United States

  • Loyola Center for Health at Burr Ridge

    Burr Ridge, Illinois, 60527, United States

  • Loyola Medicine Homer Glen

    Homer Glen, Illinois, 60491, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Marjorie Weinberg Cancer Center at Loyola-Gottlieb

    Melrose Park, Illinois, 60160, United States

  • Marshfield Medical Center - Minocqua

    Minocqua, Wisconsin, 54548, United States

  • Marshfield Medical Center - Weston

    Weston, Wisconsin, 54476, United States

  • Marshfield Medical Center-EC Cancer Center

    Eau Claire, Wisconsin, 54701, United States

  • Marshfield Medical Center-Marshfield

    Marshfield, Wisconsin, 54449, United States

  • Marshfield Medical Center-Rice Lake

    Rice Lake, Wisconsin, 54868, United States

  • Marshfield Medical Center-River Region at Stevens Point

    Stevens Point, Wisconsin, 54482, United States

  • Mary Greeley Medical Center

    Ames, Iowa, 50010, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • McFarland Clinic - Ames

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa, 50501, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Mercy Clinic-Rolla-Cancer and Hematology

    Rolla, Missouri, 65401, United States

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas, 72903, United States

  • Mercy Hospital Joplin

    Joplin, Missouri, 64804, United States

  • Mercy Hospital Oklahoma City

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital Saint Louis

    St Louis, Missouri, 63141, United States

  • Mercy Hospital South

    St Louis, Missouri, 63128, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Mercy Hospital Washington

    Washington, Missouri, 63090, United States

  • Mercy Infusion Center - Chippewa

    St Louis, Missouri, 63109, United States

  • Mercy Oncology and Hematology - Clayton-Clarkson

    Ballwin, Missouri, 63011, United States

  • MetroHealth Medical Center

    Cleveland, Ohio, 44109, United States

  • Michigan Healthcare Professionals Pontiac

    Pontiac, Michigan, 48341, United States

  • Monmouth Medical Center

    Long Branch, New Jersey, 07740, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, 10461, United States

  • MyMichigan Medical Center Saginaw

    Saginaw, Michigan, 48601, United States

  • MyMichigan Medical Center Tawas

    Tawas City, Michigan, 48764, United States

  • Newland Medical Associates-Clarkston

    Clarkston, Michigan, 48346, United States

  • Newland Medical Associates-Pontiac

    Pontiac, Michigan, 48341, United States

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois, 60201, United States

  • NorthShore University HealthSystem-Glenbrook Hospital

    Glenview, Illinois, 60026, United States

  • NorthShore University HealthSystem-Highland Park Hospital

    Highland Park, Illinois, 60035, United States

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois, 60045, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • OSF Saint Anthony's Health Center

    Alton, Illinois, 62002, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Oncology Hematology Associates of Saginaw Valley PC

    Saginaw, Michigan, 48604, United States

  • Pacific Gynecology Specialists

    Seattle, Washington, 98104, United States

  • Pali Momi Medical Center

    ‘Aiea, Hawaii, 96701, United States

  • PeaceHealth Saint John Medical Center

    Longview, Washington, 98632, United States

  • PeaceHealth Saint Joseph Medical Center

    Bellingham, Washington, 98225, United States

  • PeaceHealth Southwest Medical Center

    Vancouver, Washington, 98664, United States

  • PeaceHealth United General Medical Center

    Sedro-Woolley, Washington, 98284, United States

  • Phelps Health Delbert Day Cancer Institute

    Rolla, Missouri, 65401, United States

  • Pocono Medical Center

    East Stroudsburg, Pennsylvania, 18301, United States

  • Prisma Health Cancer Institute - Butternut

    Greenville, South Carolina, 29605, United States

  • Prisma Health Cancer Institute - Easley

    Easley, South Carolina, 29640, United States

  • Prisma Health Cancer Institute - Eastside

    Greenville, South Carolina, 29615, United States

  • Prisma Health Cancer Institute - Faris

    Greenville, South Carolina, 29605, United States

  • Prisma Health Cancer Institute - Greer

    Greer, South Carolina, 29650, United States

  • Prisma Health Cancer Institute - Seneca

    Seneca, South Carolina, 29672, United States

  • Prisma Health Cancer Institute - Spartanburg

    Boiling Springs, South Carolina, 29316, United States

  • Prisma Health Greenville Memorial Hospital

    Greenville, South Carolina, 29605, United States

  • Providence Alaska Medical Center

    Anchorage, Alaska, 99508, United States

  • Providence Cancer Institute Clackamas Clinic

    Clackamas, Oregon, 97015, United States

  • Providence Newberg Medical Center

    Newberg, Oregon, 97132, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Regional Cancer Partnership

    Everett, Washington, 98201, United States

  • Providence Regional Cancer System-Aberdeen

    Aberdeen, Washington, 98520, United States

  • Providence Regional Cancer System-Centralia

    Centralia, Washington, 98531, United States

  • Providence Regional Cancer System-Lacey

    Lacey, Washington, 98503, United States

  • Providence Regional Cancer System-Shelton

    Shelton, Washington, 98584, United States

  • Providence Regional Cancer System-Yelm

    Yelm, Washington, 98597, United States

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California, 91505, United States

  • Providence Saint Mary Regional Cancer Center

    Walla Walla, Washington, 99362, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Providence Willamette Falls Medical Center

    Oregon City, Oregon, 97045, United States

  • Queen's Cancer Cenrer - POB I

    Honolulu, Hawaii, 96813, United States

  • Queen's Cancer Center - Kuakini

    Honolulu, Hawaii, 96817, United States

  • Queen's Cancer Center - Pearlridge

    ‘Aiea, Hawaii, 96701, United States

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

  • Rambam Medical Center

    Haifa, 31096, Israel

  • Research Medical Center

    Kansas City, Missouri, 64132, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • SSM Health Good Samaritan

    Mount Vernon, Illinois, 62864, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho, 83687, United States

  • Saint Charles Health System

    Bend, Oregon, 97701, United States

  • Saint Charles Health System-Redmond

    Redmond, Oregon, 97756, United States

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho, 83687, United States

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho, 83301, United States

  • Saint Mary's Oncology/Hematology Associates of West Branch

    West Branch, Michigan, 48661, United States

  • Saint Patrick Hospital - Community Hospital

    Missoula, Montana, 59802, United States

  • San Juan City Hospital

    San Juan, 00936, Puerto Rico

  • Shaare Zedek Medical Center

    Jerusalem, 91031, Israel

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, 63136, United States

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, 63376, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, 63141, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, 63129, United States

  • Straub Clinic and Hospital

    Honolulu, Hawaii, 96813, United States

  • Swedish Cancer Institute-Edmonds

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute-Issaquah

    Issaquah, Washington, 98029, United States

  • Swedish Medical Center-Ballard Campus

    Seattle, Washington, 98107, United States

  • Swedish Medical Center-Cherry Hill

    Seattle, Washington, 98122-5711, United States

  • Swedish Medical Center-First Hill

    Seattle, Washington, 98122, United States

  • The Cancer Center of Hawaii-Liliha

    Honolulu, Hawaii, 96817, United States

  • The Cancer Center of Hawaii-Pali Momi

    ‘Aiea, Hawaii, 96701, United States

  • The James Graham Brown Cancer Center at University of Louisville

    Louisville, Kentucky, 40202, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

    Ypsilanti, Michigan, 48197, United States

  • Trinity Health Medical Center - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health Medical Center - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    Ann Arbor, Michigan, 48106, United States

  • Trinity Health Saint Joseph Mercy Oakland Hospital

    Pontiac, Michigan, 48341, United States

  • Trinity Health Saint Mary Mercy Livonia Hospital

    Livonia, Michigan, 48154, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California, 92612, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • University Oncology Associates

    Clovis, California, 93611, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio, 45069, United States

  • University of Hawaii Cancer Center

    Honolulu, Hawaii, 96813, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas, 66211, United States

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas, 66205, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, 87106, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

  • University of Vermont and State Agricultural College

    Burlington, Vermont, 05405, United States

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin, 53718, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792, United States

  • UofL Health Medical Center Northeast

    Louisville, Kentucky, 40245, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee, 37204, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Vanderbilt-Ingram Cancer Center Cool Springs

    Franklin, Tennessee, 37067, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

  • Walter Reed National Military Medical Center

    Bethesda, Maryland, 20889-5600, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

  • Wilcox Memorial Hospital and Kauai Medical Clinic

    Lihue, Hawaii, 96766, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.